Stoxline.com
android_stock_chart
Stock Chart

Stoxline Lite

Stoxline Pro

Option Calculator
Stoxline
Mobile

Home | Charts | Showcases | Stock Ranks | Options | ETFs | Educations

 
Tweet this page
Share on Facebook
Share on Google+

7 Binary Options

 

Enter Stock Symbol:  

Caladrius Bio (CLBS)

4.63 0.11 (2.43%)

04-20 16:00

Open:

4.57

Pre. Close:

4.52

High:

4.68

Low:

4.57

Volume:

11,489

Market Cap:

44M

Stock Price Prediction (Update at 5:00pm est.)

If tomorrow:

Open lower

Open higher

High:

4.687 - 4.713

4.713 - 4.737

Low:

4.5 - 4.535

4.535 - 4.566

Close:

4.58 - 4.63

4.63 - 4.676

Technical analysis  (as of: 2018-04-20 4:28:23 PM)

Overall:

      

Stoxline posted a NEUTRAL today, upgraded from lower rating. This stock seems to stay at current move trend, but it could change at anytime. So it is not a good time to buy or sell, stay at where you are until next BUY or SELL signal.

Target:

Six months: 6.49     One year: 7.24

Support:

Support1: 4.51    Support2: 3.75

Resistance:

Resistance1: 5.55    Resistance2: 6.20

Pivot:

5.02

Moving Averages:

MA(5): 4.71     MA(20): 5.20

MA(100): 4.39     MA(250): 4.21

MACD:

MACD(12,26): -0.16     Signal(12,26,9): -0.06

%K %D:

%K(14,3): 3.67     %D(3): 6.43

RSI:

RSI(14): 36.42

52-Week:

High: 6.35  Low: 2.63  Change(%): -1.5

Average Vol(K):

3-Month: 7785  10-Days 2880

Strong Sell ★★ Sell ★★★ Neutral ★★★★ Buy ★★★★★ Strong Buy

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
CLBS has closed above bottom band by 14.2%. Bollinger Bands are 16.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

2018-04-11T08:00:00-04:00
Your Daily Pharma Scoop: vTv Therapeutics Plunges, Spectrum Provides Updated Data, Selecta Sees Pullback On Data

2018-04-10T11:30:26-04:00
Caladrius Bio's CLBS12 nabs accelerated review status in Japan for critical limb ischemia

2018-03-22T18:39:06-04:00
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript

2018-03-13T09:15:54-04:00
Japan-based study underway for Caladrius Bio's CD34 cell therapy in critical limb ischemia

2018-03-10T08:00:00-05:00
3 Things In Biotech, March 9: Amgen Rises, BioTime Advances, Caladrius Updates

2018-03-09T11:51:14-05:00
Your Daily Pharma Scoop: Progenics Rallies, Merck To Partner With Eisai, Teva Upsizes Debt Offering

2018-03-09T10:03:51-05:00
Key events next week - healthcare (continued #6)

2018-03-08T10:54:02-05:00
Caladrius reports "preliminary data" from mid-stage study of T1D candidate CLBS03; shares down 5%

Financial Analysis

Growth

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.

Profitability

Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.

Solvency

Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.

Efficiency

Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.

Click here to get more fundamental analysis.

 

Free Technical Analysis Charts

Stock Basics & Statistics

Sector:  Healthcare

Industry:  Biotechnology Medical Research

Shares Out. (M)

9.55

Shares Float (M)

1.69

% Held by Insiders

83.00

% Held by Institutions

16.50

Shares Short (K)

37

Shares Short Prior Month (K)

Stock Financials

EPS

-2.780

EPS Est. Current Year

-2.420

EPS Est. Next Year

-2.950

EPS Est. Next Quarter

-0.770

Forward EPS

1.#IO

Book Value (p.s.)

0.940

PEG Ratio

Profit Margin

Operating Margin

Return on Assets (ttm)

39.3

Return on Equity (ttm)

83.0

Qtrly Rev. Growth

Gross Profit (p.s.)

-0.013

Sales Per Share

EBITDA (p.s.)

-2.354

Qtrly Earnings Growth

Operating Cash Flow (M)

Levered Free Cash Flow (M)

atoplab.com

Valuation

P/E

-1.67

P/E Growth Ratio

0.02

P/BV

4.93

P/S

P/CF

Dividend Yield

Dividends & Splits

Dividend

Dividend Pay Date

Invalid DateTime.

Ex-Dividend Date

Invalid DateTime.

Forward Dividend

Last Split Date

Last Split Ratio

-1e+010

 

(c) 2006-2017 Stoxline.com | Contact us | NYSE, NASDAQ, AMEX Stock symbols

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.